(+86)-400-900-4166

Elacridar,98%

(The order shall be subject to the English name)
Product No.:E33100 CAS.:143664-11-3 Molecular formula:C₃₄H₃₃N₃O₅ MDL:MFCD00912604 Brand:Acmec

Guess you like

Name:
Elacridar
CAS No.:
143664-11-3
Molecular formula:
C₃₄H₃₃N₃O₅
Molecular weight:
563.64
Density:
1.264±0.06 g/cm3(Predicted)
MeltingPoint:
216-218°C
BoilingPoint:
701.6±60.0°C(Predicted)
Solubility:
DMSO:41 mg/mL (72.74 mM);Ethanol:<1 mg/mL;Water:<1 mg/mL
WaterSolubility:
<1 mg/mL
Preservation conditions:
-20°C,Dark,Dry
InChIKey:
OSFCMRGOZNQUSW-UHFFFAOYSA-N
InChI:
InChI=1S/C34H33N3O5/c1-40-28-9-5-7-26-32(28)36-31-25(33(26)38)6-4-8-27(31)34(39)35-24-12-10-21(11-13-24)14-16-37-17-15-22-18-29(41-2)30(42-3)19-23(22)20-37/h4-13,18-19H,14-17,20H2,1-3H3,(H,35,39)(H,36,38)
Pubchem ID:

Biological Activity:
Elacridar (GF120918; GW0918) is a P-glycoprotein inhibitor, and has been used both in vitro and in vivo as a tool inhibitor of P-glycoprotein (Pgp) to investigate the role of transporters in the disposition of various test molecules.
Target: P-glycoprotein
In vitro, GF120918A demonstrated high plasma protein binding across species, although a definitive protein binding evaluation was precluded by poor recovery, particularly in buffer and in mouse, rat, and dog plasma. GF120918A did not demonstrate potent inhibition of several human cytochrome P450 enzymes evaluated in vitro, with IC(50) values well above concentrations anticipated to be achieved in vivo. Together, these data confirm the utility of GF120918A as a tool P-glycoprotein inhibitor in preclinical species and offer additional guidance on preclinical dose regimens likely to produce P-glycoprotein-mediated effects.

Solvent & Solubility: 10 mM in DMSO

Grade of hazardous chemicals:
For detailed properties of compounds, click“143664-11-3
technical information
History browsing record
Copyright Shanghai Acmec Biochemical Technology Co., Ltd. All Rights Reservied.
        沪ICP备18007380号-1